Novo Nordisk A/S Common Stock (NY:NVO)

37.32 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

99 100 Next >

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further ↗

November 06, 2025

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through.

Via Stocktwits

'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera ↗

November 06, 2025

Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.

Via Investor's Business Daily

Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy ↗

November 06, 2025

Novo Nordisk (NVO) exemplifies affordable growth investing with strong expansion, reasonable valuation, high profitability, and a solid dividend.

Via Chartmill

Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes ↗

November 06, 2025

A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.

Via Benzinga

Topics Government

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

November 06, 2025

Via Stocktwits

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs ↗

November 04, 2025

Via Stocktwits

An Overview of Novo Nordisk's Earnings ↗

November 04, 2025

Via Benzinga

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal ↗

November 05, 2025

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

Via Stocktwits

Topics Law Enforcement

Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars

November 05, 2025

The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo...

Via MarketMinute

Topics Economy

Novo Nordisk Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Novo Nordisk reported third-quarter financial results on Wednesday. The transcript from the company's earnings call has been provided below.

Via Benzinga

Topics Earnings

Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides

November 05, 2025

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...

Via MarketMinute

Topics Economy Intellectual Property Supply Chain

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗

November 05, 2025

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.

Via Benzinga

Prediction: Novo Nordisk Will Soar by 2026 ↗

November 05, 2025

Novo Nordisk stock just crashed -- but new drugs, smart acquisitions, and Wall Street upgrades could set up one of the biggest pharma rebounds of 2026.

Via The Motley Fool

Novo Nordisk Skids After Cutting Its Outlook For The Third Time This Year ↗

November 05, 2025

The Wegovy and Ozempic maker cut its 2025 sales outlook for the third time.

Via Investor's Business Daily

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗

November 05, 2025

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Via The Motley Fool

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs ↗

November 05, 2025

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

Via Benzinga

Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise ↗

November 04, 2025

Via Stocktwits

Here's Why Shares in Viking Therapeutics Shot Higher in October ↗

November 05, 2025

Three factors took Viking's shares higher in the month.

Via The Motley Fool

Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap? ↗

November 05, 2025

Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.

Via Stocktwits

Topics Lawsuit

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It ↗

November 04, 2025

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.

Via Benzinga

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House ↗

November 04, 2025

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide...

Via Benzinga

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb ↗

November 04, 2025

Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.

Via Benzinga

Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion ↗

November 04, 2025

Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.

Via Investor's Business Daily

Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters ↗

November 04, 2025

Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.

Via Stocktwits

Should You Buy Novo Nordisk Stock Before the Huge Investor Update? ↗

November 04, 2025

The company is preparing to launch a more convenient form of its weight loss treatment that has investors excited.

Via The Motley Fool

Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

November 04, 2025

Via Benzinga

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets ↗

November 03, 2025

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Via Stocktwits

Topics Earnings

Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks

November 03, 2025

Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of...

Via MarketMinute

Topics Artificial Intelligence Economy

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.